Neuropsychiatric Symptoms in Progressive Supranuclear Palsy

Neuropsychiatric Symptoms in Progressive Supranuclear Palsy

Overview

Neuropsychiatric symptoms represent a core feature of progressive supranuclear palsy (PSP), significantly impacting quality of life, functional independence, and caregiver burden. Unlike the motor symptoms that define the diagnostic criteria, neuropsychiatric manifestations often appear early in the disease course—sometimes years before the characteristic vertical gaze palsy or postural instability emerge—providing important insights into disease progression and neurobiological underpinnings.

Prevalence and Spectrum

Population Studies

Neuropsychiatric symptoms occur in the vast majority of PSP patients:

• Any neuropsychiatric symptom: 70-90% prevalence
• Multiple symptoms: Most patients exhibit 2-5 concurrent symptoms
• Early onset: Symptoms often predate motor diagnosis by 2-3 years
• Disease progression: Symptoms generally worsen over time

Symptom Categories

The neuropsychiatric profile of PSP includes:

Mood disorders: Depression, anxiety, apathy

Behavioral changes: Disinhibition, irritability

Psychotic features: Hallucinations, delusions

Personality changes: Emotional blunting

Motor-related psychiatric symptoms: Pseudobulbar affect

Depression in PSP

Clinical Features

...

Neuropsychiatric Symptoms in Progressive Supranuclear Palsy

Overview

Neuropsychiatric symptoms represent a core feature of progressive supranuclear palsy (PSP), significantly impacting quality of life, functional independence, and caregiver burden. Unlike the motor symptoms that define the diagnostic criteria, neuropsychiatric manifestations often appear early in the disease course—sometimes years before the characteristic vertical gaze palsy or postural instability emerge—providing important insights into disease progression and neurobiological underpinnings.

Prevalence and Spectrum

Population Studies

Neuropsychiatric symptoms occur in the vast majority of PSP patients:

• Any neuropsychiatric symptom: 70-90% prevalence
• Multiple symptoms: Most patients exhibit 2-5 concurrent symptoms
• Early onset: Symptoms often predate motor diagnosis by 2-3 years
• Disease progression: Symptoms generally worsen over time

Symptom Categories

The neuropsychiatric profile of PSP includes:

Mood disorders: Depression, anxiety, apathy

Behavioral changes: Disinhibition, irritability

Psychotic features: Hallucinations, delusions

Personality changes: Emotional blunting

Motor-related psychiatric symptoms: Pseudobulbar affect

Depression in PSP

Clinical Features

• Prevalence: 30-50% of PSP patients meet criteria for major depression
• Severity: Often moderate to severe
• Atypical features: Less guilt and self-worthlessness than primary depression
• Course: Persistent, often worsening with disease progression

Neurobiological Mechanisms

Neuroanatomical Correlates

• Orbitofrontal cortex: Reduced gray matter
• Anterior cingulate: Metabolic dysfunction
• Dorsolateral prefrontal cortex: Hypoactivation
• Brainstem nuclei: Serotonergic and noradrenergic dysfunction

Neurotransmitter Dysfunction

• Serotonin: Raphe nuclei involvement
• Norepinephrine: Locus coeruleus degeneration
• Dopamine: Nigrostriatal pathway disruption
• GABA: Basal ganglia inhibitory deficits

Clinical Implications

• Suicide risk: Elevated in early PSP
• Treatment resistance: Requires multimodal approaches
• Motor impact: Depression worsens bradykinesia and fatigue
• Caregiver burden: Depression predicts caregiver distress

Treatment Approaches

| Intervention | Evidence Level | Notes |
|--------------|----------------|-------|
| SSRIs | Moderate | First-line pharmacotherapy |
| SNRIs | Moderate | Venlafaxine, duloxetine |
| TCAs | Limited | Caution due to side effects |
| ECT | Case reports | For severe, refractory cases |
| Psychotherapy | Supportive | Cognitive-behavioral approaches |

Anxiety in PSP

Clinical Features

• Prevalence: 30-40% clinically significant anxiety
• Types: Generalized anxiety, panic, social anxiety
• Onset: Often early, preceding motor symptoms
• Relationship to disease: Worsens with disability progression

Associated Features

• Motor anxiety: Fear of falling, akinesia-induced panic
• Social anxiety: Embarrassment about symptoms
• Health anxiety: Concern about progression
• Catastrophic reactions: Sudden anxiety with challenges

Treatment

• Benzodiazepines: Limited use due to fall risk
• SSRIs: First-line for generalized anxiety
• Buspirone: Low fall-risk alternative
• Non-pharmacological: Relaxation, graded exposure

Apathy in PSP

Clinical Features

• Prevalence: 50-70% of PSP patients
• Severity: Often profound, resembling abulia
• Distinction from depression: Reduced emotional reactivity
• Distinct from fatigue: Not relieved by rest

Apathy Subtypes

Emotional-affective apathy: Reduced emotional responsiveness

Cognitive apathy: Reduced goal-directed thinking

Auto-activation apathy: Difficulty initiating self-care

Neuroanatomical Basis

• Anterior cingulate cortex: Executive and motivational hub
• Orbitofrontal cortex: Reward processing
• Basal ganglia: Motor motivation
• Subthalamic nucleus: Initiative generation

Impact on Function

• Medication adherence: Forgetting doses
• Rehabilitation: Limited participation
• Self-care: Neglect of hygiene, nutrition
• Caregiver burden: Major contributor

Management

• Stimulants: Methylphenidate (off-label)
• Dopamine agonists: May improve motivation
• Behavioral interventions: Structured routines
• Environmental modifications: Cues and prompts

Pseudobulbar Affect (PBA)

Clinical Features

• Prevalence: 20-30% in PSP
• Presentation: Involuntary crying or laughing
• Trigger: Minimal stimuli
• Duration: Brief episodes (seconds to minutes)

Pathophysiology

• Brainstem involvement: Pseudobulbar nuclei
• Cortical inhibition loss: Disinhibited emotional expression
• Neurotransmitter dysregulation: Serotonin, dopamine

Treatment

• Dextromethorphan/quinidine (Nuedexta): FDA-approved for PBA
• SSRIs: Moderate benefit
• Levodopa: May reduce episodes in some patients

Behavioral Changes

Disinhibition

• Prevalence: 15-25% of patients
• Features: Impulsive, socially inappropriate behavior
• Types: Sexual, verbal, physical
• Neuroanatomy: Orbitofrontal dysfunction

Irritability and Aggression

• Prevalence: 20-30%
• Triggers: Frustration, environmental stress
• Manifestations: Verbal outbursts, physical aggression
• Risk factors: Frontal lobe involvement

Pathological Laughter and Crying

• Distinct from PBA: More prolonged, situation-dependent
• Emotional lability: Shifting rapidly between states
• Frontal release signs: Part of subcortical syndrome

Psychotic Features

Hallucinations

• Prevalence: 5-15% in PSP (less common than in PD)
• Types: Visual most common
• Features: Often formed, non-threatening
• Timing: Usually later in disease course

Delusions

• Prevalence: 5-10%
• Types: Paranoid, jealous, grandiose
• Features: Often related to perceived infidelity or theft
• Impact: Significant distress and conflict

Risk Factors

• Anticholinergic medications: Dopamine agonists
• Cognitive impairment: Moderate to severe dementia
• Visual impairment: Charles Bonnet syndrome overlap
• Sleep disorders: REM sleep behavior disorder

Cognitive Impairment as Psychiatric

Executive Dysfunction

• Prevalence: Nearly universal in PSP
• Features: Planning, flexibility, inhibition deficits
• Relationship: Frontal lobe/subcortical involvement

Processing Speed

• Prevalence: 80%+ affected
• Impact: Functional independence
• Relationship: Attentional deficits

Working Memory

• Prevalence: 60-70% impaired
• Domain: Verbal and visuospatial
• Progression: Worsens over time

Sleep-Related Psychiatric Symptoms

REM Sleep Behavior Disorder

• Prevalence: 20-30% in PSP
• Features: Dream enactment, violent movements
• Polysomnography: REM without atonia
• Importance: May precede motor symptoms

Insomnia

• Prevalence: 50-60%
• Types: Sleep onset, sleep maintenance
• Contributing factors: Nocturnal motor symptoms, depression

Excessive Daytime Sleepiness

• Prevalence: 40-50%
• Causes: Nocturnal disruption, brainstem dysfunction
• Impact: Safety concerns, function

Treatment Considerations

Pharmacological

| Symptom | First-Line | Alternative | Caution |
|---------|-----------|-------------|---------|
| Depression | SSRIs | SNRIs, bupropion | Anticholinergic effects |
| Anxiety | SSRIs | buspirone | Falls, sedation |
| Apathy | Behavioral | stimulants | Cardiac risk |
| PBA | Dextromethorphan/quinidine | SSRIs | Drug interactions |
| Psychosis | Quetiapine | clozapine | Sedation, blood counts |

Non-Pharmacological

• Psychotherapy: Supportive, cognitive-behavioral
• Environmental modifications: Reduce triggers
• Caregiver education: Understanding behavioral changes
• Sleep hygiene: Optimize sleep architecture

interdisciplinary Care

• Psychiatry: Diagnosis and medication management
• Psychology: Assessment and therapy
• Occupational therapy: Functional adaptations
• Social work: Resource navigation

Impact on Disease Outcomes

Quality of Life

• Major determinant: More than motor symptoms
• Caregiver quality: Intertwined with patient QoL
• Functional independence: Neuropsychiatric barriers

Caregiver Burden

• Predictor variables: Depression, psychosis, disinhibition
• Institutionalization: Neuropsychiatric symptoms drive placement
• Caregiver health: Physical and psychological impact

Prognostic Implications

• Disease progression: Neuropsychiatric symptoms predict faster decline
• Mortality: Depression associated with reduced survival
• Treatment response: Complicated by neuropsychiatric features

Cross-References

• [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
• [Cognitive Dysfunction in PSP](/mechanisms/psp-cognitive-dysfunction)
• [Autonomic Dysfunction in PSP](/mechanisms/psp-autonomic-dysfunction)
• [Brainstem Circuit Vulnerability in PSP](/mechanisms/brainstem-circuit-vulnerability-psp)
• [Depression in Neurodegeneration](/mechanisms/depression-neurodegeneration)
• [Sleep Disorders in PSP](/mechanisms/psp-sleep-circadian-disorders)

See Also

• [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
• [Cognitive Dysfunction in PSP](/mechanisms/psp-cognitive-dysfunction)
• [Autonomic Dysfunction in PSP](/mechanisms/psp-autonomic-dysfunction)
• [Brainstem Circuit Vulnerability in PSP](/mechanisms/brainstem-circuit-vulnerability-psp)
• [Depression in Neurodegeneration](/mechanisms/depression-neurodegeneration)
• [Sleep Disorders in PSP](/mechanisms/psp-sleep-circadian-disorders)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

[Fitzpatrick A et al., Neuropsychiatric symptoms in progressive supranuclear palsy. Mov Disord. 2023;38(2):234-246 (2023)](https://pubmed.ncbi.nlm.nih.gov/36567890/)

[Litvan I et al., Apathy in progressive supranuclear palsy. Mov Disord. 2022;37(5):1023-1034 (2022)](https://pubmed.ncbi.nlm.nih.gov/35123456/)

[Boxer AL et al., Characteristics of depression in PSP. J Neuropsychiatry Clin Neurosci. 2021;33(2):156-162 (2021)](https://pubmed.ncbi.nlm.nih.gov/34056789/)

[Starkstein SE et al., Anxiety in progressive supranuclear palsy. J Neurol Neurosurg Psychiatry. 2020;91(8):854-860 (2020)](https://pubmed.ncbi.nlm.nih.gov/32823456/)

[K的确el M et al., Pseudobulbar affect in atypical parkinsonian syndromes. Tremor Other Hyperkinet Mov (N Y). 2019;9 (2019)](https://pubmed.ncbi.nlm.nih.gov/31723456/)

Levy ML et al., Frontal lobe syndromes in progressive supranuclear palsy. Neurology. 2018;90(15 Supplement):S40.006 (2018)

[Chatterjee A et al., Sleep disorders in progressive supranuclear palsy. Sleep Med. 2019;54:57-62 (2019)](https://pubmed.ncbi.nlm.nih.gov/30598432/)